Published in Am J Gastroenterol on November 23, 2010
Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut (2012) 2.60
RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. Am J Physiol Gastrointest Liver Physiol (2014) 2.10
Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients (2012) 2.10
Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol (2011) 1.89
Brain-gut-microbe communication in health and disease. Front Physiol (2011) 1.59
Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol (2013) 1.56
Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology (2012) 1.52
Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil (2011) 1.23
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2013) 1.20
Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms? Neurogastroenterol Motil (2012) 1.14
Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol (2012) 1.11
Brain-Gut Interactions in IBS. Front Pharmacol (2012) 1.10
The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam (2012) 1.09
Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One (2012) 1.08
Irritable bowel syndrome: a microbiome-gut-brain axis disorder? World J Gastroenterol (2014) 1.06
Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver (2015) 1.03
Irritable bowel syndrome: emerging paradigm in pathophysiology. World J Gastroenterol (2014) 1.03
Diet-microbiota interactions and their implications for healthy living. Nutrients (2013) 1.01
Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol (2014) 1.00
Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities. Front Psychiatry (2015) 0.96
New perspectives in the diagnosis and management of enteric neuropathies. Nat Rev Gastroenterol Hepatol (2013) 0.92
The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease. Clin Transl Gastroenterol (2015) 0.92
Microflora modulation of motility. J Neurogastroenterol Motil (2011) 0.91
The microbiota link to irritable bowel syndrome: an emerging story. Gut Microbes (2012) 0.91
Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression. Biol Blood Marrow Transplant (2013) 0.88
Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastroenterol (2014) 0.88
Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol (2014) 0.87
IBS-like symptoms in patients with ulcerative colitis. Clin Exp Gastroenterol (2015) 0.86
What does irritable bowel syndrome share with non-alcoholic fatty liver disease? World J Gastroenterol (2013) 0.85
A Distinct Profile of Tryptophan Metabolism along the Kynurenine Pathway Downstream of Toll-Like Receptor Activation in Irritable Bowel Syndrome. Front Pharmacol (2012) 0.85
Antibiotic-Induced Depletion of Murine Microbiota Induces Mild Inflammation and Changes in Toll-Like Receptor Patterns and Intestinal Motility. Microb Ecol (2015) 0.85
Transcript levels of Toll-Like Receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis. BMC Gastroenterol (2011) 0.82
The interplay of the gut microbiome, bile acids, and volatile organic compounds. Gastroenterol Res Pract (2015) 0.81
Editorial: toll-like receptor expression in irritable bowel syndrome: on the alert for a microbial threat? Am J Gastroenterol (2011) 0.81
Methodological issues in the study of intestinal microbiota in irritable bowel syndrome. World J Gastroenterol (2014) 0.80
The microbiome and colorectal neoplasia: environmental modifiers of dysbiosis. Curr Gastroenterol Rep (2013) 0.79
Cytokine Response after Stimulation with Key Commensal Bacteria Differ in Post-Infectious Irritable Bowel Syndrome (PI-IBS) Patients Compared to Healthy Controls. PLoS One (2015) 0.79
Gut-central nervous system axis is a target for nutritional therapies. Nutr J (2012) 0.79
Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol (2016) 0.78
Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients (2016) 0.78
Multispecies probiotic protects gut barrier function in experimental models. World J Gastroenterol (2014) 0.78
TLR4 upregulates CBS expression through NF-κB activation in a rat model of irritable bowel syndrome with chronic visceral hypersensitivity. World J Gastroenterol (2015) 0.76
Irritable Bowel Syndrome: A gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol (2016) 0.75
Dysbiotic infection in the stomach. World J Gastroenterol (2015) 0.75
Microvasculature remodeling in the mouse lower gut during inflammaging. Sci Rep (2017) 0.75
Irritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic Implications. Clujul Med (2014) 0.75
Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes (2016) 0.75
Increased Expression of Toll-Like Receptors 4, 5, and 9 in Small Bowel Mucosa from Patients with Irritable Bowel Syndrome. Biomed Res Int (2017) 0.75
Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterol (2017) 0.75
Human Intestinal Barrier Function in Health and Disease. Clin Transl Gastroenterol (2016) 0.75
Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study. United European Gastroenterol J (2017) 0.75
Close association between intestinal microbiota and irritable bowel syndrome. Eur J Clin Microbiol Infect Dis (2017) 0.75
Post-Infectious Irritable Bowel Syndrome. Curr Gastroenterol Rep (2017) 0.75
The gut flora as a forgotten organ. EMBO Rep (2006) 7.42
Gut microbiota composition correlates with diet and health in the elderly. Nature (2012) 6.94
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology (2005) 5.75
Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A (2010) 5.02
Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol (2010) 4.45
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol (2009) 3.99
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol (2006) 3.24
Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol (2006) 2.93
Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol (2009) 2.73
Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry (2008) 2.52
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut (2011) 2.49
Multireplicon genome architecture of Lactobacillus salivarius. Proc Natl Acad Sci U S A (2006) 2.43
Exploring the diversity of the bifidobacterial population in the human intestinal tract. Appl Environ Microbiol (2009) 2.34
Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology (2006) 2.28
Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut (2012) 2.24
Functional genome analysis of Bifidobacterium breve UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. Proc Natl Acad Sci U S A (2011) 2.22
Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog (2008) 2.21
The role of substance P in inflammatory disease. J Cell Physiol (2004) 2.19
Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A (2010) 2.11
Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc Natl Acad Sci U S A (2012) 2.09
Celiac disease and irritable bowel-type symptoms. Am J Gastroenterol (2002) 2.07
Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res (2007) 1.99
Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology (2011) 1.96
Systematic review on the management of chronic constipation in North America. Am J Gastroenterol (2005) 1.85
The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 1.79
Recommendations for probiotic use--2008. J Clin Gastroenterol (2008) 1.76
Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology (2006) 1.73
The mycobacteria story in Crohn's disease. Am J Gastroenterol (2005) 1.71
Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis (2013) 1.63
An update on the use and investigation of probiotics in health and disease. Gut (2013) 1.62
Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio (2012) 1.59
Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol (2008) 1.56
Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut (2008) 1.54
Celiac disease and the transition from childhood to adulthood: a 28-year follow-up. Am J Gastroenterol (2004) 1.53
Gastroenterology in developing countries: issues and advances. World J Gastroenterol (2009) 1.53
The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes (2012) 1.52
Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol (2012) 1.51
Radiologic imaging in cystic fibrosis: cumulative effective dose and changing trends over 2 decades. Chest (2011) 1.49
Radiation exposure from diagnostic imaging among patients with gastrointestinal disorders. Clin Gastroenterol Hepatol (2011) 1.48
Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J Am Coll Cardiol (2009) 1.44
Microbiomic analysis of the bifidobacterial population in the human distal gut. ISME J (2009) 1.43
Host-microbe interactions that facilitate gut colonization by commensal bifidobacteria. Trends Microbiol (2012) 1.42
Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol (2008) 1.42
Passing the bug--translocation, bacteremia, and sepsis in the intensive care unit patient: is intestinal decontamination the answer? Crit Care Med (2011) 1.40
World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol (2012) 1.39
A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci (2009) 1.39
Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol (2011) 1.34
Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol (2007) 1.33
A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. J Clin Gastroenterol (2013) 1.32
Categorization of the gut microbiota: enterotypes or gradients? Nat Rev Microbiol (2012) 1.31
Culture-independent analysis of desulfovibrios in the human distal colon of healthy, colorectal cancer and polypectomized individuals. FEMS Microbiol Ecol (2009) 1.31
Association of NOD2 with Crohn's disease in a homogenous Irish population. Eur J Hum Genet (2003) 1.30
Probiotic effects on inflammatory bowel disease. J Nutr (2007) 1.29
Irritable bowel syndrome: towards biomarker identification. Trends Mol Med (2009) 1.29
Mycobacterium avium subsp. Paratuberculosis (MAP) as a modifying factor in Crohn's disease. Inflamm Bowel Dis (2010) 1.27
Gut memories: towards a cognitive neurobiology of irritable bowel syndrome. Neurosci Biobehav Rev (2011) 1.25
Bacterial DNA within granulomas of patients with Crohn's disease--detection by laser capture microdissection and PCR. Am J Gastroenterol (2004) 1.21
The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol (2009) 1.16
Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol (2013) 1.16
Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. Am J Clin Nutr (2009) 1.15
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
Probiotic colonization of the adherent mucus layer of HT29MTXE12 cells attenuates Campylobacter jejuni virulence properties. Infect Immun (2010) 1.12
Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol Gastrointest Liver Physiol (2005) 1.12
Intestinal tuberculosis mimicking Crohn's disease: lessons relearned in a new era. Eur J Gastroenterol Hepatol (2007) 1.12
Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol (2008) 1.11
Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci (2010) 1.11
The normal intestinal microbiota. Curr Opin Infect Dis (2007) 1.11
Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis. Dig Dis Sci (2010) 1.10
Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol (2008) 1.10
Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol (2010) 1.10
Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome? Brain Behav Immun (2011) 1.09
The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam (2012) 1.09
Ribose utilization by the human commensal Bifidobacterium breve UCC2003. Microb Biotechnol (2009) 1.09
Endoluminal delivery of radiofrequency energy to the gastroesophageal junction in uncomplicated GERD: efficacy and potential mechanism of action. Am J Gastroenterol (2002) 1.07
Loss of vagal anti-inflammatory effect: in vivo visualization and adoptive transfer. Am J Physiol Regul Integr Comp Physiol (2009) 1.07
Irritable bowel syndrome: role of food in pathogenesis and management. J Dig Dis (2009) 1.06
Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res (2005) 1.06
Movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes (2012) 1.06
Identification of TLR10 as a key mediator of the inflammatory response to Listeria monocytogenes in intestinal epithelial cells and macrophages. J Immunol (2013) 1.03
Targeting the microbiota to address diet-induced obesity: a time dependent challenge. PLoS One (2013) 1.01
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes (2013) 1.01